Annexin Pharmaceuticals AB (publ)

www.annexinpharma.com

Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company in the Annexin A5 field, for the treatment of various cardiovascular diseases. The Company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for the acute treatment of patients with cardiovascular diseases with vascular damages and inflammation. The Company also has a comprehensive patent portfolio for the treatment of diseases caused by vascular damage and inflammation. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of Annexin A5. The production process is patented. ANXV has the ability to protect and repair the blood vessels as well as counteract the inflammation. ANXV is therefore expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major ones, such as heart attack. ANXV has the potential to become a First-In-Class drug (a product with new and unique mechanisms of action which is the first of its kind on the market) for several patient groups where there is considerable unmet demand for medical treatment.

Read more

Reach decision makers at Annexin Pharmaceuticals AB (publ)

Lusha Magic

Free credit every month!

Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company in the Annexin A5 field, for the treatment of various cardiovascular diseases. The Company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for the acute treatment of patients with cardiovascular diseases with vascular damages and inflammation. The Company also has a comprehensive patent portfolio for the treatment of diseases caused by vascular damage and inflammation. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of Annexin A5. The production process is patented. ANXV has the ability to protect and repair the blood vessels as well as counteract the inflammation. ANXV is therefore expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major ones, such as heart attack. ANXV has the potential to become a First-In-Class drug (a product with new and unique mechanisms of action which is the first of its kind on the market) for several patient groups where there is considerable unmet demand for medical treatment.

Read more
icon

Country

icon

City (Headquarters)

Stockholm

icon

Employees

1-10

icon

Founded

2014

icon

Social

  • icon
  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Board Member

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Operating Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Executive Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Financial Officer

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(11)

Reach decision makers at Annexin Pharmaceuticals AB (publ)

Free credits every month!

My account

Sign up now to uncover all the contact details